Literature DB >> 7504032

Functional conservation of the neutralizing domains on the external envelope glycoprotein of cosmopolitan and melanesian strains of human T cell leukemia/lymphoma virus type I.

H Hoshino1, T Nakamura, Y Tanaka, I Miyoshi, R Yanagihara.   

Abstract

To determine if the immunodominant neutralizing epitopes on the external envelope glycoprotein of the recently identified sequence variants of human T cell leukemia/lymphoma virus type I (HTLV-I) from Melanesia are functionally conserved, sera from Japanese patients with adult T cell leukemia and from HTLV-I-infected Melanesians of Papua New Guinea and the Solomon Islands were tested for neutralizing antibodies by use of vesicular stomatitis virus pseudotypes bearing envelope antigens of Japanese and Melanesian HTLV-I strains. Neutralizing antibody titers of the Japanese and Melanesian sera and of monoclonal and polyclonal antibodies directed against a known neutralizing epitope on the external envelope glycoprotein of HTLV-I were equivalent against the Japanese and Melanesian HTLV-I pseudotypes. The demonstrated two-way cross-neutralization between Japanese and Melanesian strains of HTLV-I indicates that their antigenic determinants for neutralization are functionally indistinguishable and that HTLV-I exists as a single serotype worldwide.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504032     DOI: 10.1093/infdis/168.6.1368

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Entry of human T-cell leukemia virus type 1 is augmented by heparin sulfate proteoglycans bearing short heparin-like structures.

Authors:  Atsushi Tanaka; Atsushi Jinno-Oue; Nobuaki Shimizu; Ariful Hoque; Takahisa Mori; Salequl Islam; Youko Nakatani; Masahiko Shinagawa; Hiroo Hoshino
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region.

Authors:  N Kariya; K Hayashi; H Hoshino; Y Tanaka; T R Koirala; N Ohara; K Miyamoto; T Akagi
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.

Authors:  Y Tanaka; R Tanaka; E Terada; Y Koyanagi; N Miyano-Kurosaki; N Yamamoto; E Baba; M Nakamura; H Shida
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Genetic and phylogenetic analyses of human T-cell lymphotropic virus type I variants from Melanesians with and without spastic myelopathy.

Authors:  V R Nerurkar; K J Song; R R Melland; R Yanagihara
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

5.  Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins.

Authors:  Altar M Munis; Maha Tijani; Mark Hassall; Giada Mattiuzzo; Mary K Collins; Yasuhiro Takeuchi
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

6.  Lentivector Producer Cell Lines with Stably Expressed Vesiculovirus Envelopes.

Authors:  Maha Tijani; Altar M Munis; Christopher Perry; Khaled Sanber; Marta Ferraresso; Tarit Mukhopadhyay; Michael Themis; Ilaria Nisoli; Giada Mattiuzzo; Mary K Collins; Yasuhiro Takeuchi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-08-07       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.